{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:58:24Z","timestamp":1787237904720,"version":"build-2736575974"},"reference-count":81,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hemolytic anemia due to immune function is one of the major causes of acquired hemolytic anemia. In recent years, as more is known about the immune system, these entities have become better understood and their treatment improved. In this section, we will discuss three areas in which this progress has been apparent.<\/jats:p>\n                  <jats:p>In Section I, Dr. Peter Hillmen outlines the recent findings in the pathogenesis of paroxysmal nocturnal hemoglobinuria (PNH), relating the biochemical defect (the lack of glycosylphosphatidylinositol [GPI]-linked proteins on the cell surface) to the clinical manifestations, particularly hemolysis (and its effects) and thrombosis. He discusses the pathogenesis of the disorder in the face of marrow dysfunction insofar as it is known. His major emphasis is on innovative therapies that are designed to decrease the effectiveness of complement activation, since the lack of cellular modulation of this system is the primary cause of the pathology of the disease. He recounts his considerable experience with a humanized monoclonal antibody against C5, which has a remarkable effect in controlling the manifestations of the disease. Other means of controlling the action of complement include replacing the missing modulatory proteins on the cell surface; these studies are not as developed as the former agent.<\/jats:p>\n                  <jats:p>In Section II, Dr. Alan Schreiber describes the biochemistry, genetics, and function of the Fc\u03b3 receptors and their role in the pathobiology of autoimmune hemolytic anemia and idiopathic thrombocytopenic purpura due to IgG antibodies. He outlines the complex varieties of these molecules, showing how they vary in genetic origin and in function. These variations can be related to three-dimensional topography, which is known in some detail. Liganding IgG results in the transduction of a signal through the tyrosine-based activation motif and Syk signaling. The role of these receptors in the pathogenesis of hematological diseases due to IgG antibodies is outlined and the potential of therapy of these diseases by regulation of these receptors is discussed.<\/jats:p>\n                  <jats:p>In Section III, Dr. Wendell Rosse discusses the forms of autoimmune hemolytic anemia characterized by antibodies that react preferentially in the cold\u2013cold agglutinin disease and paroxysmal cold hemoglobinuria (PCH). The former is due to IgM antibodies with a common but particular structure that reacts primarily with carbohydrate or carbohydrate-containing antigens, an interaction that is diminished at body temperature. PCH is a less common but probably underdiagnosed illness due to an IgG antibody reacting with a carbohydrate antigen; improved techniques for the diagnosis of PCH are described. Therapy for the two disorders differs somewhat because of the differences in isotype of the antibody. Since the hemolysis in both is primarily due to complement activation, the potential role of its control, as by the monoclonal antibody described by Dr. Hillmen, is discussed.<\/jats:p>","DOI":"10.1182\/asheducation-2004.1.48","type":"journal-article","created":{"date-parts":[[2004,11,19]],"date-time":"2004-11-19T21:03:01Z","timestamp":1100898181000},"page":"48-62","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":50,"title":["Immune-Mediated Hemolytic Anemia"],"prefix":"10.1182","volume":"2004","author":[{"given":"Wendell F.","family":"Rosse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hillmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021215274996900_R1","doi-asserted-by":"crossref","unstructured":"Parker CJ. Historical aspects of paroxysmal nocturnal haemoglobinuria: \u2018defining the disease\u2019. Br J Haematol. 2002;117:3\u201322.","DOI":"10.1046\/j.1365-2141.2002.03374.x"},{"key":"2020021215274996900_R2","doi-asserted-by":"crossref","unstructured":"Hall C, Richards SJ, Hillmen P. The glycosylphosphatidylinositol anchor and paroxysmal nocturnal haemoglobinuria\/aplasia model. Acta Haematologica. 2002;108:219\u2013230.","DOI":"10.1159\/000065658"},{"key":"2020021215274996900_R3","doi-asserted-by":"crossref","unstructured":"Miyata T, Takeda J, Iida Y, et al. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science. 1993;259:1318\u20131320.","DOI":"10.1126\/science.7680492"},{"key":"2020021215274996900_R4","doi-asserted-by":"crossref","unstructured":"Takeda J, Miyata T, Kawagoe K, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell. 1993;73:703\u2013711.","DOI":"10.1016\/0092-8674(93)90250-T"},{"key":"2020021215274996900_R5","doi-asserted-by":"crossref","unstructured":"Miyata T, Yamada N, Iida Y, et al. Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1994;330:249\u2013255.","DOI":"10.1056\/NEJM199401273300404"},{"key":"2020021215274996900_R6","doi-asserted-by":"crossref","unstructured":"Yamashina M, Ueda E, Kinoshita T, et al. Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1990;323:1184\u20131189","DOI":"10.1056\/NEJM199010253231707"},{"key":"2020021215274996900_R7","doi-asserted-by":"crossref","unstructured":"Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333:1253\u20131258.","DOI":"10.1056\/NEJM199511093331904"},{"key":"2020021215274996900_R8","unstructured":"Socie G, Mary JY, de Gramont A, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet. 1996;348:573\u2013577."},{"key":"2020021215274996900_R9","doi-asserted-by":"crossref","unstructured":"Nishimura JI, Kanakura Y, Ware RE, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore). 2004;83:193\u2013207","DOI":"10.1097\/01.md.0000126763.68170.46"},{"key":"2020021215274996900_R10","unstructured":"Nafa K, Bessler M, Mason P, et al. Factor V Leiden mutation investigated by amplification created restriction enzyme site (ACRES) in PNH patients with and without thrombosis. Haematologica. 1996;81:540\u2013542."},{"key":"2020021215274996900_R11","doi-asserted-by":"crossref","unstructured":"Wiedmer T, Hall SE, Ortel TL, Kane WH, Rosse WF, Sims PJ. Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. Blood. 1993;82:1192\u20131196.","DOI":"10.1182\/blood.V82.4.1192.1192"},{"key":"2020021215274996900_R12","doi-asserted-by":"crossref","unstructured":"Hugel B, Socie G, Vu T, et al. Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood. 1999;93:3451\u20133456.","DOI":"10.1182\/blood.V93.10.3451.410k27_3451_3456"},{"key":"2020021215274996900_R13","doi-asserted-by":"crossref","unstructured":"Saso R, Marsh J, Cevreska L, et al. Bone marrow transplants for paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1999;104:392\u2013396.","DOI":"10.1046\/j.1365-2141.1999.01195.x"},{"key":"2020021215274996900_R14","doi-asserted-by":"crossref","unstructured":"Richards SJ, Rawstron AC, Hillmen P. Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuria. Cytometry. 2000;42:223\u2013233.","DOI":"10.1002\/1097-0320(20000815)42:4<223::AID-CYTO2>3.0.CO;2-D"},{"key":"2020021215274996900_R15","doi-asserted-by":"crossref","unstructured":"Brodsky RA, Mukhina GL, Li S, et al. Improved detection and characterization of paroxysmal nocturnal hemoglobinuria using fluorescent aerolysin. Am J Clin Pathol. 2000;114:459\u2013466.","DOI":"10.1093\/ajcp\/114.3.459"},{"key":"2020021215274996900_R16","doi-asserted-by":"crossref","unstructured":"Rotoli B, Luzzatto L. Paroxysmal nocturnal haemoglobinuria. Semin Hematol. 1989;26:201\u2013207.","DOI":"10.1016\/S0950-3536(89)80010-1"},{"key":"2020021215274996900_R17","doi-asserted-by":"crossref","unstructured":"McMullin MF, Hillmen P, Jackson J, Ganly P, Luzzatto L. Tissue plasminogen activator for hepatic vein thrombosis in paroxysmal nocturnal haemoglobinuria. J Intern Med. 1994;235:85\u201389.","DOI":"10.1111\/j.1365-2796.1994.tb01037.x"},{"key":"2020021215274996900_R18","doi-asserted-by":"crossref","unstructured":"Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood. 2003;102:3587\u20133591.","DOI":"10.1182\/blood-2003-01-0009"},{"key":"2020021215274996900_R19","doi-asserted-by":"crossref","unstructured":"Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004;350:552\u2013559.","DOI":"10.1056\/NEJMoa031688"},{"key":"2020021215274996900_R20","doi-asserted-by":"crossref","unstructured":"Nishimura J, Phillips KL, Ware RE, et al. Efficient retrovirus-mediated PIG-A gene transfer and stable restoration of GPI-anchored protein expression in cells with the PNH phenotype. Blood. 2001;97:3004\u20133010.","DOI":"10.1182\/blood.V97.10.3004"},{"key":"2020021215274996900_R21","doi-asserted-by":"crossref","unstructured":"Rother RP, Rollins SA, Mennone J, et al. Expression of recombinant transmembrane CD59 in paroxysmal nocturnal hemoglobinuria B-cells confers resistance to human complement. Blood. 1994;84:2604\u20132611.","DOI":"10.1182\/blood.V84.8.2604.2604"},{"key":"2020021215274996900_R22","unstructured":"Sah A, Ridley SH, Richards SJ, et al. Prodaptin-CD59, a membrane-targeted recombinant CD59, coats PNH red cells in vitro and in vivo protecting both from human complement mediated lysis. Hematology J. 2004;5 (suppl. 2):S207."},{"key":"2020021215274996900_R23","doi-asserted-by":"crossref","unstructured":"Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol. 2001;19:275\u2013290.","DOI":"10.1146\/annurev.immunol.19.1.275"},{"key":"2020021215274996900_R24","doi-asserted-by":"crossref","unstructured":"te Velde AA, de Waal Malefijt R, Huijbens RJ, de Vries JE, Figdor CG. IL-10 stimulates monocyte Fc gamma R surface expression and cytotoxic activity. Distinct regulation of antibody-dependent cellular cytotoxicity by IFN-gamma, IL-4, and IL-10. J Immunol. 1992;149:4048\u20134052.","DOI":"10.4049\/jimmunol.149.12.4048"},{"key":"2020021215274996900_R25","doi-asserted-by":"crossref","unstructured":"Fischer G, Schneider EM, LL LM, et al. CD64 surface expression on neutrophils is transiently upregulated in patients with septic shock. Intensive Care Med. 2001;27:1848\u20131852.","DOI":"10.1007\/s00134-001-1135-z"},{"key":"2020021215274996900_R26","doi-asserted-by":"crossref","unstructured":"Hartnell A, Kay AB, Wardlaw AJ. IFN-gamma induces expression of Fc gamma RIII (CD16) on human eosinophils. J Immunol. 1992;148:1471\u20131478.","DOI":"10.4049\/jimmunol.148.5.1471"},{"key":"2020021215274996900_R27","doi-asserted-by":"crossref","unstructured":"Woof JM, Burton DR. Human antibody-Fc receptor interactions illuminated by crystal structures. Nat Rev Immunol. 2004;4:89\u201399.","DOI":"10.1038\/nri1266"},{"key":"2020021215274996900_R28","doi-asserted-by":"crossref","unstructured":"Maxwell KF, Powell MS, Hulett MD, et al. Crystal structure of the human leukocyte Fc receptor, Fc gammaRIIa. Nat Struct Biol. 1999;6:437\u2013442.","DOI":"10.1038\/8241"},{"key":"2020021215274996900_R29","doi-asserted-by":"crossref","unstructured":"Sondermann P, Huber R, Oosthuizen V, Jacob U. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature. 2000;406:267\u2013273.","DOI":"10.1038\/35018508"},{"key":"2020021215274996900_R30","doi-asserted-by":"crossref","unstructured":"Sondermann P, Kaiser J, Jacob U. Molecular basis for immune complex recognition: a comparison of Fc-receptor structures. J Mol Biol. 2001;309:737\u2013749.","DOI":"10.1006\/jmbi.2001.4670"},{"key":"2020021215274996900_R31","doi-asserted-by":"crossref","unstructured":"Radaev S, Sun PD. Recognition of IgG by Fcgamma receptor. The role of Fc glycosylation and the binding of peptide inhibitors. J Biol Chem. 2001;276:16478\u201316483.","DOI":"10.1074\/jbc.M100351200"},{"key":"2020021215274996900_R32","doi-asserted-by":"crossref","unstructured":"Mimura Y, Sondermann P, Ghirlando R, et al. Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding. J Biol Chem. 2001;276:45539\u201345547.","DOI":"10.1074\/jbc.M107478200"},{"key":"2020021215274996900_R33","doi-asserted-by":"crossref","unstructured":"Edberg JC, Kimberly RP. Cell type-specific glycoforms of Fc gamma RIIIa (CD16): differential ligand binding. J Immunol. 1997;159:3849\u20133857.","DOI":"10.4049\/jimmunol.159.8.3849"},{"key":"2020021215274996900_R34","doi-asserted-by":"crossref","unstructured":"Drescher B, Witte T, Schmidt RE. Glycosylation of FcgammaRIII in N163 as mechanism of regulating receptor affinity. Immunology. 2003;110:335\u2013340.","DOI":"10.1046\/j.1365-2567.2003.01743.x"},{"key":"2020021215274996900_R35","doi-asserted-by":"crossref","unstructured":"Warmerdam PA, van de Winkel JG, Vlug A, Westerdaal NA, Capel PJ. A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. J Immunol. 1991;147:1338\u20131343.","DOI":"10.4049\/jimmunol.147.4.1338"},{"key":"2020021215274996900_R36","doi-asserted-by":"crossref","unstructured":"Karassa FB, Trikalinos TA, Ioannidis JP. Role of the Fcgamma receptor IIa polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. Arthritis Rheum. 2002;46:1563\u20131571.","DOI":"10.1002\/art.10306"},{"key":"2020021215274996900_R37","doi-asserted-by":"crossref","unstructured":"Wu J, Edberg JC, Redecha PB, et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest. 1997;100:1059\u20131070.","DOI":"10.1172\/JCI119616"},{"key":"2020021215274996900_R38","doi-asserted-by":"crossref","unstructured":"Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. Fc gammaRIIIa-158V\/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L\/R\/H phenotype. Blood. 1997;90:1109\u20131114.","DOI":"10.1182\/blood.V90.3.1109"},{"key":"2020021215274996900_R39","doi-asserted-by":"crossref","unstructured":"Salmon JE, Edberg JC, Kimberly RP. Fc gamma receptor III on human neutrophils. Allelic variants have functionally distinct capacities. J Clin Invest. 1990;85:1287\u20131295.","DOI":"10.1172\/JCI114566"},{"key":"2020021215274996900_R40","doi-asserted-by":"crossref","unstructured":"Indik ZK, Park JG, Hunter S, Schreiber AD. The molecular dissection of Fc gamma receptor mediated phagocytosis. Blood. 1995;86:4389\u20134399.","DOI":"10.1182\/blood.V86.12.4389.bloodjournal86124389"},{"key":"2020021215274996900_R41","doi-asserted-by":"crossref","unstructured":"Cambier JC. New nomenclature for the Reth motif (or ARH1\/TAM\/ARAM\/YXXL). Immunol Today. 1995;16:110.","DOI":"10.1016\/0167-5699(95)80105-7"},{"key":"2020021215274996900_R42","doi-asserted-by":"crossref","unstructured":"Van den Herik-Oudijk IE, Capel PJ, van der Bruggen T, Van de Winkel JG. Identification of signaling motifs within human Fc gamma RIIa and Fc gamma RIIb isoforms. Blood. 1995;85:2202\u20132211.","DOI":"10.1182\/blood.V85.8.2202.bloodjournal8582202"},{"key":"2020021215274996900_R43","doi-asserted-by":"crossref","unstructured":"Hunter S, Indik ZK, Kim MK, Cauley MD, Park JG, Schreiber AD. Inhibition of Fcgamma receptor-mediated phagocytosis by a nonphagocytic Fcgamma receptor. Blood. 1998;91:1762\u20131768.","DOI":"10.1182\/blood.V91.5.1762"},{"key":"2020021215274996900_R44","doi-asserted-by":"crossref","unstructured":"Reth M. Antigen receptor tail clue. Nature. 1989;338:383\u2013384.","DOI":"10.1038\/338383b0"},{"key":"2020021215274996900_R45","doi-asserted-by":"crossref","unstructured":"Mitchell MA, Huang MM, Chien P, Indik ZK, Pan XQ, Schreiber AD. Substitutions and deletions in the cytoplasmic domain of the phagocytic receptor Fc gamma RIIA: effect on receptor tyrosine phosphorylation and phagocytosis. Blood. 1994;84:1753\u20131759.","DOI":"10.1182\/blood.V84.6.1753.1753"},{"key":"2020021215274996900_R46","doi-asserted-by":"crossref","unstructured":"Strzelecka A, Kwiatkowska K, Sobota A. Tyrosine phosphorylation and Fcgamma receptor-mediated phagocytosis. FEBS Lett. 1997;400:11\u201314.","DOI":"10.1016\/S0014-5793(96)01359-2"},{"key":"2020021215274996900_R47","doi-asserted-by":"crossref","unstructured":"Park JG, Murray RK, Chien P, Darby C, Schreiber AD. Conserved cytoplasmic tyrosine residues of the gamma subunit are required for a phagocytic signal mediated by Fc gamma RIIIA. J Clin Invest. 1993;92:2073\u20132079.","DOI":"10.1172\/JCI116804"},{"key":"2020021215274996900_R48","unstructured":"Hunter S, Huang MM, Indik ZK, Schreiber AD. Fc gamma RIIA-mediated phagocytosis and receptor phosphorylation in cells deficient in the protein tyrosine kinase Src. Exp Hematol. 1993;21:1492\u20131497."},{"key":"2020021215274996900_R49","doi-asserted-by":"crossref","unstructured":"Fitzer-Attas CJ, Lowry M, Crowley MT, et al. Fcgamma receptor-mediated phagocytosis in macrophages lacking the Src family tyrosine kinases Hck, Fgr, and Lyn. J Exp Med. 2000;191:669\u2013682.","DOI":"10.1084\/jem.191.4.669"},{"key":"2020021215274996900_R50","doi-asserted-by":"crossref","unstructured":"Johnson SA, Pleiman CM, Pao L, Schneringer J, Hippen K, Cambier JC. Phosphorylated immunoreceptor signaling motifs (ITAMs) exhibit unique abilities to bind and activate Lyn and Syk tyrosine kinases. J Immunol. 1995;155:4596\u20134603.","DOI":"10.4049\/jimmunol.155.10.4596"},{"key":"2020021215274996900_R51","doi-asserted-by":"crossref","unstructured":"Ghazizadeh S, Bolen JB, Fleit HB. Tyrosine phosphorylation and association of Syk with Fc gamma RII in monocytic THP-1 cells. Biochem J. 1995;305( Pt 2):669\u2013674.","DOI":"10.1042\/bj3050669"},{"key":"2020021215274996900_R52","doi-asserted-by":"crossref","unstructured":"Kimura T, Sakamoto H, Appella E, Siraganian RP. Conformational changes induced in the protein tyrosine kinase p72syk by tyrosine phosphorylation or by binding of phosphorylated immunoreceptor tyrosine-based activation motif peptides. Mol Cell Biol. 1996;16:1471\u20131478.","DOI":"10.1128\/MCB.16.4.1471"},{"key":"2020021215274996900_R53","doi-asserted-by":"crossref","unstructured":"Indik ZK, Park JG, Pan XQ, Schreiber AD. Induction of phagocytosis by a protein tyrosine kinase. Blood. 1995;85:1175\u20131180.","DOI":"10.1182\/blood.V85.5.1175.bloodjournal8551175"},{"key":"2020021215274996900_R54","doi-asserted-by":"crossref","unstructured":"Matsuda M, Park JG, Wang DC, Hunter S, Chien P, Schreiber AD. Abrogation of the Fc gamma receptor IIA-mediated phagocytic signal by stem-loop Syk antisense oligonucleotides. Mol Biol Cell. 1996;7:1095\u20131106.","DOI":"10.1091\/mbc.7.7.1095"},{"key":"2020021215274996900_R55","doi-asserted-by":"crossref","unstructured":"Stenton GR, Kim MK, Nohara O, et al. Aerosolized Syk antisense suppresses Syk expression, mediator release from macrophages, and pulmonary inflammation. J Immunol. 2000;164:3790\u20133797.","DOI":"10.4049\/jimmunol.164.7.3790"},{"key":"2020021215274996900_R56","doi-asserted-by":"crossref","unstructured":"Williams Y, Lynch S, McCann S, Smith O, Feighery C, Whelan A. Correlation of platelet Fc gammaRIIA polymorphism in refractory idiopathic (immune) thrombocytopenic purpura. Br J Haematol. 1998;101:779\u2013782.","DOI":"10.1046\/j.1365-2141.1998.00802.x"},{"key":"2020021215274996900_R57","doi-asserted-by":"crossref","unstructured":"Clynes R, Ravetch JV. Cytotoxic antibodies trigger inflammation through Fc receptors. Immunity. 1995;3:21\u201326.","DOI":"10.1016\/1074-7613(95)90155-8"},{"key":"2020021215274996900_R58","doi-asserted-by":"crossref","unstructured":"Berney T, Shibata T, Merino R, et al. Murine autoimmune hemolytic anemia resulting from Fc gamma receptor-mediated erythrophagocytosis: protection by erythropoietin but not by interleukin-3, and aggravation by granulocyte-macrophage colony-stimulating factor. Blood. 1992;79:2960\u20132964.","DOI":"10.1182\/blood.V79.11.2960.bloodjournal79112960"},{"key":"2020021215274996900_R59","doi-asserted-by":"crossref","unstructured":"Wright JF, Blanchette VS, Wang H, et al. Characterization of platelet-reactive antibodies in children with varicella-associated acute immune thrombocytopenic purpura (ITP). Br J Haematol. 1996;95:145\u2013152.","DOI":"10.1046\/j.1365-2141.1996.d01-1872.x"},{"key":"2020021215274996900_R60","doi-asserted-by":"crossref","unstructured":"Chan H, Moore JC, Finch CN, Warkentin TE, Kelton JG. The IgG subclasses of platelet-associated autoantibodies directed against platelet glycoproteins IIb\/IIIa in patients with idiopathic thrombocytopenic purpura. Br J Haematol. 2003;122:818\u2013824.","DOI":"10.1046\/j.1365-2141.2003.04509.x"},{"key":"2020021215274996900_R61","doi-asserted-by":"crossref","unstructured":"Stasi R, Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc. 2004;79:504\u2013522.","DOI":"10.4065\/79.4.504"},{"key":"2020021215274996900_R62","doi-asserted-by":"crossref","unstructured":"Gehrs BC, Friedberg RC. Autoimmune hemolytic anemia. Am J Hematol. 2002;69:258\u2013271.","DOI":"10.1002\/ajh.10062"},{"key":"2020021215274996900_R63","doi-asserted-by":"crossref","unstructured":"Sewell WA, Jolles S. Immunomodulatory action of intravenous immunoglobulin. Immunology. 2002;107:387\u2013393.","DOI":"10.1046\/j.1365-2567.2002.01545.x"},{"key":"2020021215274996900_R64","doi-asserted-by":"crossref","unstructured":"Teeling JL, Jansen-Hendriks T, Kuijpers TW, et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood. 2001;98:1095\u20131099.","DOI":"10.1182\/blood.V98.4.1095"},{"key":"2020021215274996900_R65","doi-asserted-by":"crossref","unstructured":"Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001;291:484\u2013486.","DOI":"10.1126\/science.291.5503.484"},{"key":"2020021215274996900_R66","unstructured":"Zilow G, Kirschfink M, Roelcke D. Red cell destruction in cold agglutinin disease. [Review]. Infusionsther Transfusionsmed. 1994;21:410\u2013415."},{"key":"2020021215274996900_R67","unstructured":"Kirschfink M, Knoblauch K, Roelcke D. Activation of complement by cold agglutinins. [Review]. Infusionsther Transfusionsmed. 1994;21:405\u2013409."},{"key":"2020021215274996900_R68","doi-asserted-by":"crossref","unstructured":"Pascual V, Victor K, Spellerberg M, et al. VH restriction among human cold agglutinins. The VH4-21 gene segment is required to encode anti-I and anti-i specificities. J Immunol. 1992;149:2337\u20132344.","DOI":"10.4049\/jimmunol.149.7.2337"},{"key":"2020021215274996900_R69","doi-asserted-by":"crossref","unstructured":"Thorpe SJ, Turner CE, Stevenson FK, et al. Human monoclonal antibodies encoded by the V4-34 gene segment show cold agglutinin activity and variable multireactivity which correlates with the predicted charge of the heavy-chain variable region. Immunology. 1998;93:129\u2013136.","DOI":"10.1046\/j.1365-2567.1998.00406.x"},{"key":"2020021215274996900_R70","doi-asserted-by":"crossref","unstructured":"Potter KN, Hobby P, Klijn S, Stevenson FK, Sutton BJ. Evidence for involvement of a hydrophobic patch in framework region 1 of human V4-34 encoded Igs in recognition of the red blood cell I antigen. J Immunol. 2003;169:3777\u20133782.","DOI":"10.4049\/jimmunol.169.7.3777"},{"key":"2020021215274996900_R71","doi-asserted-by":"crossref","unstructured":"Berentsen S, Bo K, Shammas FV, Myking WO, Ulvestad E. Chronic cold agglutinin disease of the \u201cidiopathic\u201d type is a premalignant or low-grade malignant lymphoproliferative disease. APMIS. 1997;105:354\u2013362.","DOI":"10.1111\/j.1699-0463.1997.tb00581.x"},{"key":"2020021215274996900_R72","doi-asserted-by":"crossref","unstructured":"Michaux L, Dierlamm J, Wlordska I, et al. Trisomy 3 is a consistent chromosome change in malignant lymphoproliferative disorders preceded by cold agglutinin disease. Br J Haematol. 1995;91:421\u2013424.","DOI":"10.1111\/j.1365-2141.1995.tb05315.x"},{"key":"2020021215274996900_R73","doi-asserted-by":"crossref","unstructured":"Heddle NM. Acute paroxysmal cold hemoglobinuria. [Review]. Transfus Med Rev. 1989;3:219\u2013229.","DOI":"10.1016\/S0887-7963(89)70082-1"},{"key":"2020021215274996900_R74","unstructured":"Nordhagen R. Two cases of paroxysmal cold hemoglobinuria with a Donath-Landsteiner antibody reactive by the indirect antiglobulin test using anti-IgG. Transfusion. 1985;31:142\u2013144."},{"key":"2020021215274996900_R75","doi-asserted-by":"crossref","unstructured":"Sharara AI, Hillsley RE, Wax TD, Rosse WF. Paroxysmal cold hemoglobinuria associated with non-Hodgkin\u2019s lymphoma. South Med J. 1994;87:397\u2013399.","DOI":"10.1097\/00007611-199403000-00019"},{"key":"2020021215274996900_R76","doi-asserted-by":"crossref","unstructured":"Rosse WF, Adams JP. The variability of hemolysis in the cold agglutinin syndrome. Blood. 1980;56:409\u2013416.","DOI":"10.1182\/blood.V56.3.409.409"},{"key":"2020021215274996900_R77","doi-asserted-by":"crossref","unstructured":"Pujol M, Ribera JM, Jimenez C, Ribera A, Abad E, Feliu E. Essential monoclonalgammopathy with an IgM paraprotein that is a cryoglobulin with cold agglutinin and EDTA-dependent platelet antibody properties. Br J Haemat. 1998;100:603\u2013604.","DOI":"10.1046\/j.1365-2141.1998.00586.x"},{"key":"2020021215274996900_R78","doi-asserted-by":"crossref","unstructured":"Hughey CT, Brewer JW, Colosia AD, Rosse WF, Corley RB. Production of IgM hexamers by normal and autoimmune B cells: implications for the physiologic role of hexameric IgM. J Immunol. 1998;161:4091\u20134097.","DOI":"10.4049\/jimmunol.161.8.4091"},{"key":"2020021215274996900_R79","doi-asserted-by":"crossref","unstructured":"Berentsen S, Ulvestad E, Gjertsen BT, et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 2004;103:2925\u20132938.","DOI":"10.1182\/blood-2003-10-3597"},{"key":"2020021215274996900_R80","doi-asserted-by":"crossref","unstructured":"Jacobs A. Cold agglutinin hemolysis responding to fludarabine therapy. Am J Hematol1996;53:279\u2013280.","DOI":"10.1002\/(SICI)1096-8652(199612)53:4<279::AID-AJH17>3.0.CO;2-7"},{"key":"2020021215274996900_R81","doi-asserted-by":"crossref","unstructured":"Zoppi M, Oppliger R, Althaus U, Nydegger U, Reduction of plasma cold agglutinin titers by means of plasmapheresis to prepare a patient for coronary bypass surgery. Infusionsther Transfusionsmed.1993;20:19\u201322.","DOI":"10.1159\/000222800"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2004\/1\/48\/1634457\/048_062ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2004\/1\/48\/1634457\/048_062ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,30]],"date-time":"2023-04-30T06:31:36Z","timestamp":1682836296000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2004\/1\/48\/18682\/ImmuneMediated-Hemolytic-Anemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1,1]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2004.1.48","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,1,1]]}}}